Need for low cost HIV point-of-care CD4 diagnostic tests in low-resource settings. The “gold standard” for CD4 test is flow cytometry. However it is expensive, requires complex electronic machinery and mostly located in cities and urban areas, so there is a need for a low-cost, but accurate alternative.
Our goal is to fund diagnostics tests across our major disease areas to drive down costs and drive up accessibility by increasing decentralization of availability to diagnostics. Accurate and timely patient CD4 counts allow doctors to initiate and monitor antiretroviral therapy to guide treatment.
Venture backed private biotechnology company focused on HIV CD4 diagnostics
Foundation focus: Proprietary technology designed by Zyomyx that combines the benefits of specific cell capture with the ability to quantify cell count through the use of a high precision capillary assembly
Unsecured convertible note and equity
Date: May 2011; debt conversion June 2013
Co-Investors: Mylan (June 2013)
Associated funding: Additional re-investments made to develop commercialization plan and go-to-market strategy